ABOUT DIABETES
- Summary of ADA & EASD Consensus Statement12
These guidelines and treatment algorithm emphasize: - Achievement and maintenance of near normoglycemia (HbA1c <7.0%)
- Initial therapy with lifestyle intervention and metformin
- Rapid addition of medications, and transition to new regimens when target glycemic goals are not achieved or sustained
- Early addition of insulin therapy in patients who do not meet target glycemic goals
Diabetes currently affects an estimated 23.6 million people in the United States1 and more than 246
million people worldwide2, and its incidence continues to rise.
Among adults, type 2 diabetes accounts for 90-95 percent of all diagnosed cases1, and, despite advances in our understanding of the disease and new therapies, delivery devices and diagnostics, the majority of people living with type 2 diabetes are not achieving adequate control of their disease.
The fact is that living with and treating type 2 diabetes is challenging, especially with intensive insulin therapy - often involving two different types of insulin and 3-4 injections every day - is needed to keep glucose levels at in check.
Yet the ability to maintain tight control of glucose levels is vital to helping lower the risks of long-term and often serious complications of type 2 diabetes. For many, this requires steady compliance with therapy as well as modifications to lifestyle and eating habits, large and small.
According to the recent Consensus Statement from the American Diabetes Association and the European Association for the Study of Diabetes, much of the morbidity associated with long-term micro vascular and neuropathic complications can be substantially reduced by interventions that achieve glucose levels close to the non-diabetic range.3
To achieve control of diabetes, the Consensus Statement recommends transition to new therapy regimens when target glycemic levels are not met, including the early addition of insulin. In addition, when insulin is required, "insulin regimens...should be designed taking lifestyle and meal schedule into account."
Several recent studies have shown the benefits of continuous insulin infusion for patients with type 2 diabetes, especially for those who are not meeting treatment goals. Results indicate that patients may improve glycemic control with simple continuous infusion regimens and they report an increased satisfaction and quality of life.2-11
CeQur understands the many challenges of diabetes and knows that patients and those who treat them need effective and easy-to-use new technologies for better short- and long-term outcomes.
Additional Resources:
For more information about type 2 diabetes, please visit:
American Diabetes Association: http://www.diabetes.org/
U.S. CDC, National Center for Chronic Disease Prevention and Health Promotion:
http://www.cdc.gov/diabetes/
International Diabetes Federation: http://www.idf.org/
1 National Institute of Diabetes and Digestive and Kidney Diseases. National Diabetes Statistics, 2007 fact sheet. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, 2008.
2 The International Diabetes Federation Diabetes facts & figures / Prevalence. Available at http://www.idf.org/node/1087?node=264.
3 Parkner et al. Insulin and glucose profiles during CSII and long acting insulin. Diabetic Medicine 25, 585-591
4 Labrousse-Lhermine Longer term treatment CSII in type 2 diabetes. Diabetes and Metabolism 33 (2007) 253-260
5 Jennings A et al. RCT Comparing CSII and CIT in type 2 DM. Diabetes Care, 14: 8, August 1991.
6 Raskin et al. CSII versus MDI in Type 2 Diabetes 14 Center Randomized Parallel Group Study. Diabetes Care 26(9): 2598-2603, 2003
7 Raskin P et al. CSII vs MDI in type 2 diabetes. Diabetes Care 26, 9 2003
8 Herman W et al. CSII versus MDI in Older Adults type 2 DM. Diabetes Care 28, 7, July 2005
9 Berthe E et al. Effectiveness of MDI and CSII in Type 2 diabetes. Horm Metab Res 2007: 39: 224-229
10 Wainstein et al. Insulin pump therapy vs MDI in obese type 2 diabetes. Diabetic Medicine 22, 1037-1046
11 Edelman et al., A 16-Week, Open-Label, 6-Center Pilot Study Exploring Insulin Dosing Regimens Necessary To Achieve Optimal Glycemic Control in Subjects With Type 2 Diabetes Treated With Insulin Pump Therapy. ADA poster #428, June 2009
12 Nathan DM, Buse JF, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2009; 32:193-203
Among adults, type 2 diabetes accounts for 90-95 percent of all diagnosed cases1, and, despite advances in our understanding of the disease and new therapies, delivery devices and diagnostics, the majority of people living with type 2 diabetes are not achieving adequate control of their disease.
The fact is that living with and treating type 2 diabetes is challenging, especially with intensive insulin therapy - often involving two different types of insulin and 3-4 injections every day - is needed to keep glucose levels at in check.
Yet the ability to maintain tight control of glucose levels is vital to helping lower the risks of long-term and often serious complications of type 2 diabetes. For many, this requires steady compliance with therapy as well as modifications to lifestyle and eating habits, large and small.
According to the recent Consensus Statement from the American Diabetes Association and the European Association for the Study of Diabetes, much of the morbidity associated with long-term micro vascular and neuropathic complications can be substantially reduced by interventions that achieve glucose levels close to the non-diabetic range.3
To achieve control of diabetes, the Consensus Statement recommends transition to new therapy regimens when target glycemic levels are not met, including the early addition of insulin. In addition, when insulin is required, "insulin regimens...should be designed taking lifestyle and meal schedule into account."
Several recent studies have shown the benefits of continuous insulin infusion for patients with type 2 diabetes, especially for those who are not meeting treatment goals. Results indicate that patients may improve glycemic control with simple continuous infusion regimens and they report an increased satisfaction and quality of life.2-11
CeQur understands the many challenges of diabetes and knows that patients and those who treat them need effective and easy-to-use new technologies for better short- and long-term outcomes.
Additional Resources:
For more information about type 2 diabetes, please visit:
American Diabetes Association: http://www.diabetes.org/
U.S. CDC, National Center for Chronic Disease Prevention and Health Promotion:
http://www.cdc.gov/diabetes/
International Diabetes Federation: http://www.idf.org/
1 National Institute of Diabetes and Digestive and Kidney Diseases. National Diabetes Statistics, 2007 fact sheet. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, 2008.
2 The International Diabetes Federation Diabetes facts & figures / Prevalence. Available at http://www.idf.org/node/1087?node=264.
3 Parkner et al. Insulin and glucose profiles during CSII and long acting insulin. Diabetic Medicine 25, 585-591
4 Labrousse-Lhermine Longer term treatment CSII in type 2 diabetes. Diabetes and Metabolism 33 (2007) 253-260
5 Jennings A et al. RCT Comparing CSII and CIT in type 2 DM. Diabetes Care, 14: 8, August 1991.
6 Raskin et al. CSII versus MDI in Type 2 Diabetes 14 Center Randomized Parallel Group Study. Diabetes Care 26(9): 2598-2603, 2003
7 Raskin P et al. CSII vs MDI in type 2 diabetes. Diabetes Care 26, 9 2003
8 Herman W et al. CSII versus MDI in Older Adults type 2 DM. Diabetes Care 28, 7, July 2005
9 Berthe E et al. Effectiveness of MDI and CSII in Type 2 diabetes. Horm Metab Res 2007: 39: 224-229
10 Wainstein et al. Insulin pump therapy vs MDI in obese type 2 diabetes. Diabetic Medicine 22, 1037-1046
11 Edelman et al., A 16-Week, Open-Label, 6-Center Pilot Study Exploring Insulin Dosing Regimens Necessary To Achieve Optimal Glycemic Control in Subjects With Type 2 Diabetes Treated With Insulin Pump Therapy. ADA poster #428, June 2009
12 Nathan DM, Buse JF, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2009; 32:193-203